BMN 111 (vosoritide) Improves Growth Velocity in Children With Achondroplasia in Phase 2 Study
June 17, 2015 at 16:05 PM EDT
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive results of a Phase 2 proof-of-concept and dose finding study of BMN ...